Building a Regulatory Roadmap for IND, NDA, and BLA

This document is a guide that outlines the critical steps and considerations for pharmaceutical companies in building a regulatory roadmap for Investigational New Drug (IND), New Drug Applications (NDA), and Biologics License Applications (BLA). It features insights from experts at Cardinal Health Regulatory Sciences, emphasizing the importance of early and strategic engagement with regulatory bodies, particularly for small to midsize companies. The document details the significance of developing a target product profile, which guides the regulatory roadmap by identifying key factors such as patient population and treatment regimen. It also discusses the necessity of frequent communication with the FDA throughout the drug development process, highlighting various meetings that can facilitate successful submissions. Additionally, it addresses the unique considerations for IND, NDA, and BLA applications, including the importance of consistent messaging and preparation for regulatory meetings. Overall, the guide serves as a comprehensive resource for navigating the complexities of regulatory submissions.